Toggle light / dark theme

These Are the Meta-Trends Shaping the Future (at Breakneck Speed)

Life is pretty different now than it was 20 years ago, or even 10 years ago. It’s sort of exciting, and sort of scary. And hold onto your hat, because it’s going to keep changing—even faster than it already has been.

The good news is, maybe there won’t be too many big surprises, because the future will be shaped by trends that have already been set in motion. According to Singularity University co-founder and XPRIZE founder Peter Diamandis, a lot of these trends are unstoppable—but they’re also pretty predictable.

At SU’s Global Summit, taking place this week in San Francisco, Diamandis outlined some of the meta-trends he believes are key to how we’ll live our lives and do business in the (not too distant) future.

The Top 10 Companies Working to Increase Longevity

The core of what we do at Nanalyze is to tell our readers all they need to know about investing in emerging technologies. Sometimes that story is much, much bigger, and what we’re really talking about is investing in emerging industries. NewSpace is one example, launching about 15 years ago with the emergence of companies like SpaceX and Virgin Galactic. It’s probably only within the last five years that the NewSpace industry has achieved real liftoff, with dozens of startups doing everything from offering launch services to building satellites to developing business analytics from space-based imagery. While we may one day end up living on Mars, we’re more interested in living a long and fruitful life right here on Mother Earth, despite the specter of cancer and dementia. An entire industry is coalescing around human longevity, promising to beat these age-related diseases and extend our lives to biblical proportions.

We’ve been covering the topic of life extension for more than five years, beginning with a profile on an anti-aging company called Human Longevity Inc, whose founders include billionaire serial entrepreneur Peter Diamandis and J. Craig Venter, a leading genomics expert. More recently, we introduced you to nine companies developing products in regenerative medicine, a broad category that refers to restoring the structure and function of damaged tissues or organs. We also tackled the more controversial topic of young blood transfusions earlier this year, as well as covered the 2019 IPO of Precision BioSciences (DTIL), a gene-editing company that wants to fight disease and re-engineer food.

The Regenerage Show- Episode #4 — “Whole Organism Rejuvenation and Combinatorial Biologics” — Ira Pastor — Host

Peter Diamandis’ right hand man Sergey Young wants to reverse aging via his $100M Longevity Vision Fund

Great news!


Inspired by British billionaire Jim Mellon, chairman of anti-aging upstart biotech venture Juvenescence, Sergey Young unveiled a $100 million fund on Monday to catalyze the development of a comprehensive solution to counteract the damaging consequences of aging.

“I’ve never looked like my age…and with my name, I think it was predetermined that I was going to work in the space (of aging),” Young told Endpoints News. The 47-year-old considers himself a product of Peter Diamandis — the man behind the non-profit XPRIZE and venture capital fund BOLD Capital Partners — and is in charge of all things longevity at both organizations.

Startup Proposes Using Stem Cells From Placentas for Regenerative Medicine

Our ultimate mission is to make 100 years old the new 60.”


A new exploration of stem cells from placentas could drastically advance regenerative medicine. Peter Diamandis, X-Prize and Singularity University founder, recently teamed up with Robert Hariri, the founder of Celgene Cellular Therapeutics, to study these specific stem cells in the hopes of discovering new regenerative therapies.

The initiative, called Celularity, is built around the idea that stem cells found in the human placenta (which transports nutrients to fetuses as they grow) are ideal for regenerating tissue and organs. According to Celularity, the cells can be taken from any placenta, which typically just gets discarded, and placed into any human without the risk of rejection.

/* */